Physician profile
Michael H Bowman
NPI 1114958972
$3,285.27
in general payments reported to CMS, 2019-2025
48 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $88.15 · 2021: $117 · 2022: $983 · 2023: $638 · 2024: $20.83 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $424.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $350.16 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $227.54 | 2021-2022 | |
| Amgen INC. | $158.51 | 2019-2023 | Aimovig |
| Boston Scientific Corporation | $146.56 | 2019-2025 | Accolade Sr, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $142.85 | 2021-2023 | Botox, Duopa, Qulipta |
| Emd Serono, INC. | $110.23 | 2019 | |
| Lilly USA, LLC | $104.52 | 2019-2023 | Amyvid |
| Teva Pharmaceuticals USA, INC. | $101.55 | 2019-2022 | |
| Genentech USA, INC. | $93.31 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $82.99 | 2019-2023 | Rytary |
| Sk Life Science, INC. | $75.03 | 2023 | |
| Acorda Therapeutics, INC | $70.13 | 2019-2023 | Inbrija |
| Impel Pharmaceuticals INC. | $69.47 | 2023 | Trudhesa |
| Csl Behring | $68.21 | 2019-2023 | Hizentra |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.